🟢 Tiziana Life Sciences is trading 3.8% up in pre-market after last patient began dosing, completing enrollment

Tiziana Life Sciences is trading 3.8% up in pre-market at $1.09, after the last patient began dosing in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer’s disease, completing enrollment. - The company announced the milestone at 7:00 a.m. ET on October 16; its October 15 close was $1.05. - Topline data are anticipated in Q1 2027. No trading-volume or activity-level information was available, and broader pre-market indexes were mixed.